UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
BIMZELX® (bimekizumab-bkzx) is now commercially available by prescription in the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELXThe single-injection device offers convenience